{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:01:09Z","timestamp":1770987669279,"version":"3.50.1"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:p> Purpose: To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) could be safely dose-intensified with routine filgrastim support. <\/jats:p><jats:p> Patients and Methods: Eligible patients were those who were previously untreated and who had either bulky stage II, or stage III or IV lymphoma with working formulation histology D, E, F, G, H, or J; performance status \u2264 2; and acceptable end organ function. No upper age limit was specified. Therapy was dose-intensified CHOP (CHOP-DI) with filgrastim support. Each course was repeated every 14 days for six planned courses. <\/jats:p><jats:p> Results: Eighty-eight eligible patients were treated with CHOP-DI and had a median follow-up of 5.1 years on this phase II study, designated Southwest Oncology Group (SWOG) 9349. The progression-free survival was 51% at 2 years and 41% at 5 years. The overall survival was 60% at 5 years. Three fatal treatment-related events occurred. One patient with myelodysplastic syndrome was reported. <\/jats:p><jats:p> Conclusion: Treatment with CHOP-DI can be safely administered in the cooperative group setting and results in improved survival. Estimated overall survival at 5 years was 14% better than that of patients treated with standard-dose CHOP in an earlier SWOG study, although progression-free survival of 60% at 2 years\u2014the prespecified end point\u2014was not achieved. CHOP-DI, given every 2 weeks at escalated doses, is a strategy that should be tested in a future randomized clinical trial in lymphoma. <\/jats:p>","DOI":"10.1200\/jco.2003.06.137","type":"journal-article","created":{"date-parts":[[2003,6,30]],"date-time":"2003-06-30T19:58:12Z","timestamp":1057003092000},"page":"2466-2473","source":"Crossref","is-referenced-by-count":62,"title":["Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349)"],"prefix":"10.1200","volume":"21","author":[{"given":"Douglas W.","family":"Blayney","sequence":"first","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Grogan","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen R.","family":"Gaynor","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Chapman","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Harris","family":"Spiridonidis","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott I.","family":"Bearman","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Miller","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard I.","family":"Fisher","sequence":"additional","affiliation":[{"name":"From the Wilshire Oncology Medical Group, Inc, Pasadena, CA; Southwest Oncology Group Statistical Center, Seattle, WA; University of Arizona Cancer Center, Tucson, AZ; Loyola University Stritch School of Medicine, Maywood, IL; Henry Ford Hospital, Detroit, MI; Columbus Community Clinical Oncology Program, Columbus, OH; University of Kansas Medical Center, Kansas City, MO; University of Colorado School of Medicine, Denver, CO; and University of Rochester School of Medicine, Rochester, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.3.175"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.7.494"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.963"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1155"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.6.1430.1430"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2916"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"R12","unstructured":"Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res 31:1860,1971\u20131861,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008381811131"},{"key":"R17","unstructured":"Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly CHOP (CHOP-14): The new standard regimen for patients with aggressive non-Hodgkin\u2019s lymphoma (NHL) more than 60 years of age. Blood 98:S3027,2001,  (suppl 1)"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.750"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<207::AID-CNCR1311>3.0.CO;2-D"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"R23","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998\u20131932,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.389"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.423"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3025"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705013361804"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2796"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.125"},{"key":"R32","unstructured":"Kaiser U, Uebelacker I, Havemann K, et al: High-dose chemotherapy with autologous stem cell transplantation in high grade NHL: First analysis of a randomized multicenter study. Bone Marrow Transplant 21:S177,1998,  (suppl 1)"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1631"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.06.137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:27:49Z","timestamp":1653510469000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.06.137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":31,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2003,7,1]]}},"alternative-id":["10.1200\/JCO.2003.06.137"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.06.137","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}